# Tuberculosis Diagnostic Methods: Clinical Applicability, Implementation Challenges, and Integrated Testing Strategies

**Authors:** Eduarda Rabello, Fernanda de-Paris

PMC · DOI: 10.3390/pathogens15020142 · Pathogens · 2026-01-28

## TL;DR

This review evaluates TB diagnostic methods, focusing on their real-world use, challenges, and how to integrate them effectively in different healthcare settings.

## Contribution

The paper offers an implementation-focused analysis of TB diagnostics, addressing gaps in existing guidelines and emphasizing operational and contextual factors.

## Key findings

- Current TB diagnostic methods vary in effectiveness and feasibility depending on healthcare resources and infrastructure.
- Modern techniques like NAATs and LAMP offer advantages but face implementation barriers such as biosafety and workforce limitations.
- Integrated diagnostic strategies tailored to local conditions can improve TB detection and equity in testing.

## Abstract

Tuberculosis (TB) remains one of the leading causes of death from a single infectious agent worldwide, a burden further exacerbated by HIV co-infection and the increasing prevalence of drug-resistant strains. Although a wide range of laboratory diagnostic methods are currently available, their applicability, implementation, and clinical impact vary substantially across healthcare settings with different levels of complexity and resources. This review provides a comprehensive overview of the main laboratory diagnostic methods for active and latent TB, emphasizing their clinical applicability, implementation challenges, and role within integrated diagnostic strategies. Conventional approaches, such as smear microscopy and culture, are discussed alongside modern diagnostic technologies, including automated nucleic acid amplification tests (NAATs), loop-mediated isothermal amplification (LAMP), line probe assays (LPAs), next-generation sequencing (NGS), and lateral flow assays, highlighting their strengths and limitations in distinct epidemiological and operational contexts. Unlike existing WHO guidelines and prior reviews that predominantly focus on test performance and recommendation status, this review adopts an implementation-oriented perspective, critically examining diagnostic methods in light of real-world constraints, regional disparities, and evidence gaps. Particular attention is given to limitations related to laboratory infrastructure, biosafety, workforce capacity, and sustainability, as well as to under-addressed areas such as latent TB, metagenomic approaches, and the investigation of co-pathogens. By integrating WHO guidance with contextual and operational considerations, this review aims to support rational test selection and the development of flexible, integrated diagnostic workflows tailored to local health system capacity, patient populations, and clinical scenarios, thereby strengthening the effectiveness and equity of TB diagnostic strategies.

## Linked entities

- **Diseases:** Tuberculosis (MONDO:0018076)

## Full-text entities

- **Genes:** MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, INHA (inhibin subunit alpha) [NCBI Gene 3623], IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, MT1JP (metallothionein 1J, pseudogene) [NCBI Gene 4498] {aka MT1, MT1J, MT1NP, MTB}
- **Diseases:** bacterial drug resistance (MESH:D000069279), proteinuria (MESH:D011507), latent infection (MESH:D000085343), injury to (MESH:D014947), disease (MESH:D004194), inflammatory (MESH:D007249), multidrug resistance (MESH:D018088), extrapulmonary TB (MESH:D000092225), renal disease (MESH:D007674), TB of the central nervous system (MESH:D020306), -TB (MESH:D014376), hypersensitivity (MESH:D004342), HIV (MESH:D015658), tuberculous meningitis (MESH:D014390), infectious (MESH:D003141), active (OMIM:612348), HIV co-infection (MESH:D060085), C (OMIM:211750), death (MESH:D003643), pulmonary TB (MESH:D014397), infected (MESH:D007239), LTBI (MESH:D055985)
- **Chemicals:** glycolipid (MESH:D006017), silver (MESH:D012834), T- (MESH:D014316), oxygen (MESH:D010100), isoniazid (MESH:D007538), LAM (MESH:C050016), ethionamide (MESH:D005000), lipids (MESH:D008055), auramine (MESH:D001576), ESAT-6 (-), Fuchsin (MESH:D012394), RIF (MESH:D012293), fluoroquinolones (MESH:D024841), amikacin (MESH:D000583), quinolone (MESH:D015363)
- **Species:** Mycobacterium tuberculosis complex (species group) [taxon 77643], Human immunodeficiency virus 1 (no rank) [taxon 11676], Mycobacteriales (order) [taxon 85007], Mycobacterium szulgai (species) [taxon 1787], Mycobacterium riyadhense (species) [taxon 486698], Human immunodeficiency virus (species) [taxon 12721], Mycobacterium kansasii (species) [taxon 1768], Mycobacterium tuberculosis (species) [taxon 1773], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Mycobacterium marinum (species) [taxon 1781], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12942670/full.md

## References

128 references — full list in the complete paper: https://tomesphere.com/paper/PMC12942670/full.md

---
Source: https://tomesphere.com/paper/PMC12942670